Telik's proteasome program meets preclinical development milestone.

The article reports on the announcement made by Telik Inc. that its small molecule proteasome inhibitor program has met a preclinical development through an anticancer activity in preclinical models of human leukemia. According to Telik, the inhibitors are orally active, non-peptide, non-boron based which may lead to a drug candidate. Telik vice president of biology James Keck noted that the compounds were achieved through the use of their Trap computational drug discovery technology.